The 14th Five-Year Plan for the development of pharmaceutical industry

Third, the overall requirements of the Plan

 Overall development and security, comprehensively improve the modernization of the pharmaceutical industry chain, achieve stable and controllable supply chains, accelerate the transformation of innovation-driven development, cultivate new growth drivers, promote high-end, intelligent and green industries, build new advantages in international competition, improve the pharmaceutical supply security system, and better meet the diversified and multi-level health needs of the people.

In accordance with the basic principles of life first, innovation-led, systematic promotion, open cooperation, the development goals for the next five years and the vision goals for 15 years. By 2025, the main economic indicators will achieve medium-to-high growth, innovation achievements in frontier areas will be prominent, innovation momentum will be enhanced, the modernization level of the industrial chain will be significantly improved, the supply security system for pharmaceutical equipment will be further improved, and the level of internationalization will be comprehensively improved. By 2035, the strength of the pharmaceutical industry will achieve an overall jump; An innovation-driven development pattern has been fully formed, the industrial structure has been upgraded, and products with more variety and better quality have been produced to meet the health needs of the people at a higher level, providing a solid guarantee for building a healthy China in all respects.

The Plan sets out six specific goals.

First, economies of scale are growing steadily. On the basis of a comprehensive analysis of the "13th Five-Year Plan" period of the pharmaceutical industry scale economy indicators, comprehensive consideration of domestic and foreign technological development, policy changes and other factors, the "Plan" proposed that the "14th Five-Year Plan" period of the pharmaceutical industry operating income, total profits of the average annual growth rate of more than 8%, added value accounted for the proportion of all industries increased to about 5%, the concentration of leading enterprises in the industry further improved.

Second, innovation-driven transformation has achieved remarkable results. During the "13th Five-Year Plan" period, a large number of traditional pharmaceutical enterprises accelerated innovation and transformation, innovative entrepreneurial enterprises increased significantly, and the number of new drugs entering the clinical stage and R&D investment increased significantly. During the "14th Five-Year Plan" period, a large number of pharmaceutical innovation results will complete clinical research and listing, and the pharmaceutical industry will continue to increase innovation investment and accelerate innovation-driven transformation. The "Plan" proposed that during the "14th Five-Year Plan" period, the average annual growth of R&D investment in the industry was more than 10%; By 2025, the proportion of new sales of innovative products in the increase of operating income of the whole industry will further increase.

Third, the industrial chain and supply chain are stable and controllable. The advantages of large-scale systematic pharmaceutical manufacturing have been further consolidated, a number of industrialization key common technologies have made breakthroughs, and positive results have been achieved in key areas to make up for weaknesses, and a number of key enterprises with industrial ecological leading ability have been cultivated in the subdivision field.

Fourth, the ability to ensure supply continued to increase. The supply of medicines, vaccines, protective materials and diagnosis and treatment equipment for the prevention and control of major diseases is adequate, and the medical reserve system has been improved. The supply of essential drugs, small varieties of drugs, and drugs prone to shortage was stable, and the ability to ensure a number of urgently needed medicines for children and drugs for rare diseases was improved.

Fifth, the manufacturing level system is improved. The quality management of the whole life cycle of drugs and medical devices has been strengthened, and the number of generic drugs that have passed the conformance evaluation has further increased; The level of green, digital and intelligent development of enterprises has been significantly improved, the level of safety technology and management has been effectively improved, and the ability to control production safety risks has been significantly enhanced.

Sixth, international development has been accelerated in an all-round way. Pharmaceutical exports maintained growth; Chinese patent medicine "going out" breakthrough; Cultivate a number of world-renowned brands; A number of large pharmaceutical enterprises with global R&D and production layout and a high proportion of international sales have been formed.

Iv. Key tasks of the Plan

"Planning" around the development goals, put forward five key tasks to be implemented during the "14th Five-Year Plan" period, and combined with the trend of technological development, in the form of columns, put forward the pharmaceutical innovation product industrialization project, pharmaceutical industrialization technology research project, vaccine and shortage of drugs supply security project, product quality upgrade project, the pharmaceutical industry green low-carbon project and other five projects.